Coherentmarketinsightsus

  The global Hepatitis Drugs Market is projected to witness CAGR of 3.2% throughout the forecast period (2019 – 2027), owing to increasing number of regulatory approvals of hepatitis drugs. For example, in 2017 Gilead Sciences, Inc. announced that the European Commission had granted marketing authorization for Vemlidy (tenofovir alafenamide) for the treatment of chronic hepatitis B virus (HBV) infection in adults and adolescents (aged 12 years and older). The Hepatitis Drugs Market size is expected to witness remarkable growth on the forecast period owing to increasing prevalence of hepatitis. For example, according to the World Health Organization (WHO), in 2017, around 71 million people were infected by chronic hepatitis C worldwide. Furthermore, WHO considers Middle East and Europe to be probably the most affected regions with the prevalence rate of 2.3% and 1.5% respectively. Moreover, in 2016, according to the Centers for Disease Control and Prevention, arou...